58Â° Congresso Nazionale SCIVAC: Oncologia veterinaria

More documents

Recommendations

Info

58° Congresso Nazionale SCIVAC • Milano, 7-9 Marzo 2008 • Oncologia veterinaria - Alle soglie del III Millennio are dependent on DNA/cellular proliferation but are not cell cycle specific. Toxicity is usually expressed when the cell enters the S-phase and is unable to replicate. Pharmacokinetics Cyclophosphamide can be administered orally (PO) or intravenously (IV). The oral administration route shows variable bioavailability ranging from 74- 97%. Following IV administration maximal plasma concentration is achieved in 2-3 hours. Cyclophosphamide is widely distributed into body tissues. In veterinary medicine the recommended dosage for cyclophosphamide is 50 mg/m 2 PO four days per week or a single dose of 250 mg/ m 2 every 3 weeks. Injectable cyclophosphamide is administered at doses ranging from 100-300 mg/m 2 IV as often as once weekly, depending on the protocol involved. Cyclophosphamide is a prodrug that is activated by cytochrome p450 enzymes in the liver. The active 4-hydroxycyclophosphamide is rapidly metabolized to inactive 4-ketocyclophosphamide and carboxyphosphamide metabolites. Aldophosphamide spontaneously converts to phosphoramide mustard and acrolein. Phosphoramide mustard is the active anticancer agent. Acrolein is primarily responsible for the hemorrhagic cystitis complication. The main elimination route of cyclophosphamide and its metabolites is by renal excretion. Approximately 36-99% of the conventional dose is excreted in the urine within 48 hours with about 5-30% being unchanged drug. Less than 4% of the dose is recovered in feces. Toxicity Dose limiting toxicity is myelosuppression with a nadir of 7-14 days, gastrointestinal side effects, a transient increase in liver enzymes, sterile hemorrhagic cystitis, anorexia, nausea, vomiting, alopecia in susceptible breeds, and infertility. Myelosuppression is exacerbated by other drugs in common chemotherapy combination protocols. Indications Cyclophosphamide is used widely in veterinary medicine for treatment of lymphomas, leukemias, carcinomas and sarcomas in dogs and cats, mainly in combination protocols. Cyclophosphamide may be prescribed for treatment autoimmune diseases in veterinary medicine. 58
58° Congresso Nazionale SCIVAC • Milano, 7-9 Marzo 2008 • Oncologia veterinaria - Alle soglie del III Millennio Contraindications Myelosuppression, characterized by leukopenia and thrombocytopenia, necessitates dose delay. Treatment should be interrupted in patients who develop infections. Because of the importance of renal excretion, patients with renal failure should receive alternative alkylating agents or should have the dose reduced or interval increased. Guidelines for dose modification in the face of renal insufficiency have not been well established. Patients that develop sterile hemorrhagic cystitis should discontinue the use of cyclophosphamide, or should only receive the drug concurrently with the urothelial protectant compound 2-mercaptoethanesulphonate (mesna). Therapy should be discontinued in case of anaphylactic reactions, or known sensitivity. CHLORAMBUCIL Chlorambucil is an aromatic derivative of mustargen. It is the slowest acting and generally least toxic of the commonly used alkylating agents. Mechanism of action As with other classical alkylating agents, chlorambucil preferentially binds the 7-N position of guanine. Chlorambucil is a bifunctional alkylator in that it can bind to two DNA strands as well as DNA and a macromolecule. DNA damage includes base mispairing, DNA template misreading, and spontaneous depurination. Pharmacokinetics Chlorambucil is readily absorbed after oral administration, leading to peak plasma levels after 2-4 hours. Food can interfere with absorption. The dose used in veterinary medicine ranges from 2-6 mg/m 2 PO given every other day, or up to 20 mg/m 2 PO administered every 3 weeks. Chlorambucil is metabolized in the liver to an alkylating metabolite, phenyl-acetic acid mustard, which is degraded before being excreted by the kidneys. Chlorambucil is extensively protein bound. Toxicity Bone marrow suppression is the most significant side effect. Myelosuppression secondary to chlorambucil seems to be less severe than that of cyclo- 59
Page 1:
58° Congresso Nazionale SCIVAC •
Page 5 and 6:
Page 9: 58° Congresso Nazionale SCIVAC •
Page 12 and 13: 58° Congresso Nazionale SCIVAC •
Page 14 and 15: nr. 6312 Sedazione IL PASSATO È FI
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 165 and 166:
POSTER Gli estratti sono elencati i
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
show all

58Â° Congresso Nazionale SCIVAC: Oncologia veterinaria

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?